A retrospective study was conducted in France in 1998 to determine the clinical features of visceral leishmaniasis (VL) in 91 patients infected cocomitantly with human immunodeficiency virus. Our data suggest that the clinical manifestations of VL may be influenced by the immunological status, with atypical locations of Leishmania amastigotes more frequently found in severely immunocompromised patients. In such patients, the involvement of atypical locations may lead to the discovery of VL.
tient data were entered and analyzed with the use of Epi-info software (Centers for Disease Control and Prevention, Atlanta). Because the study was retrospective, data analysis was purposely descriptive, and results were presented as common descriptive statistics. In view of the results obtained, certain data were compared using the test, the Fisher exact test, and the 2 x Mann-Whitney U test.
was considered statistically P ! 0.05 significant.
Ninety-one patients with coinfection of VL and HIV were analyzed. Most of the patients (85%) lived in the following areas of southern France where Leishmania infantum infection is endemic: Nice (49 patients), Marseille (22 patients), and Toulon (6 patients). In the present study, the cases reported from the center in Nice represented all cases recorded in the Laboratory of Parasitology-Mycology at Nice University Hospital. At the centers in Marseille, Toulon, and Bondy, each separate department reported all the cases of coinfection diagnosed in the present study, as confirmed by the respective reference microbiology laboratories.
Of the 91 cases of coinfection, 63 (69%) were diagnosed from 1993 through 1996. However, only 5 cases were reported in 1997, compared with 18 in 1996. Some of these case reports have already been published [5] [6] [7] . A total of 78 males (86%) and 13 females (14%) were studied. The mean patient age was 38 years (range, 22-71 years), and the mean CD4 count was 56 cells/mm 3 (range, 0-370 cells/mm 3 ). The frequency of fever, splenomegaly, and hepatomegaly was 87%, 74%, and 49%, respectively. The clinical triad of fever, splenomegaly, and hepatomegaly was found in 43% of patients and was significantly more frequent in patients with a CD4 count of 150 ). P p .006 Anemia, leukopenia, and thrombocytopenia were noted in 94%, 88%, and 81% of the patients, respectively. Amastigotes were reported in atypical locations in 31 patients (34%); these atypical locations included the digestive tract (16 patients), the skin (7 patients), the lungs (7 patients), and the tonsils (1 patient). Atypical locations were more frequently found in patients with a CD4 count of !50 cells/mm 3 than in patients with a CD4 count of 150 cells/mm 3 (41% vs. 21%, respectively; ). P p .05 Moreover, patients with Leishmania amastigotes in atypical locations tended to have CD4 counts lower than those in patients ). P p .06 For 15 patients, the diagnosis of VL was established only when Leishmania amastigotes were found unexpectedly in atypical locations, after discovery of Leishmania infection initiated the diagnostic procedure. Endoscopic examination of these patients was performed because of the following clinical signs: diarrhea, epigastralgia, or dry cough. The main clinical characteristics of the patients are presented in table 1. For 12 patients, the diagnosis of VL was confirmed by the presence of amastigotes on bone marrow smears. For the other 3 patients, bone marrow smears were negative, but the diagnosis of VL was made later. For patient 2, the indirect immunofluorescence (IFAT) for Leishmania species was positive, and later explorative splenectomy revealed the presence of Leishmania infantum MON-1 [6] . ELISA and IFAT were negative for patients 7 and 13. At follow-up, patient 7 had clinical relapse of VL with positive bone marrow smears. Autopsy of patient 13 revealed disseminated Leishmania infection in the bone marrow, lymph nodes, liver, spleen, and gastrointestinal tract. For the 16 other patients who had Leishmania infection in atypical locations, the diagnosis of VL was made concomitantly with a reference diagnosis procedure-that is, by demonstration of amastigotes on bone marrow smears.
This series reports half of the cases of coinfection diagnosed in France during the study period [8] . The clinical manifestations of VL in HIV-infected patients did not differ significantly from those in immunocompetent individuals [9] . However, our data suggest that the clinical manifestations of VL in HIVinfected patients may be influenced by the patients' immunological status; patients with a CD4 count of !50 cells/mm 3 have a lower frequency of the clinical triad of fever, splenomegaly, and hepatomegaly and, conversely, findings of Leishmania amastigotes in atypical locations were more frequent. Leishmania amastigotes were present in atypical locations in onethird of the patients, and because systematic searches were not done, their numbers were probably underestimated. That they were significantly more frequent in severely immunocompromised patients supports the role of the response of the immune system in expression of the disease [4] .
Discovery of amastigotes in an atypical site led to the diagnosis of VL in 15 patients. Involvement of the gastrointestinal tract or the respiratory tract is not uncommon in HIV-infected patients [4, 5, 7] . In the literature, the frequency and clinical significance of VL in atypical locations are not clearly described. Leishmania species can invade many tissues asymptomatically [4] . However, parasitization should be considered in those cases in which digestive tract symptoms are present. Diarrhea has been reported in 40% of immunocompetent patients with VL who live in Sudan, 50% of those who live in India, and 60% of those who live in Brazil [10] . Nevertheless, in these countries, diarrhea may result from other diseases. In our series, perendoscopic gastrointestinal biopsies led to the unexpected diagnosis of VL in 12 patients. Endoscopy, which was performed because of the clinical symptoms, revealed no pathogens, other than Leishmania species, in 11 patients (table 1) . We cannot exclude all biases, in particular other undiagnosed conditions causing diarrhea or epigastralgia. However, our data suggest that Leishmania parasitization of the digestive tract can be symptomatic in severely immunocompromised HIV-infected patients.
Even in areas where Leishmania infection is endemic, the diagnosis of VL is not yet systematically considered by physicians caring for HIV-infected patients. In 5 patients (patients 3, 5, 10, 12, and 14; table 1), the clinical triad of fever, splenomegaly, and hepatomegaly was present with pancytopenia, suggesting that a diagnosis of VL could have been evoked prior to endoscopy. Conversely, our data suggest that it is not unusual for major clinical signs to be absent. Occult forms of VL, for which neither major clinical signs nor hematologic abnormalities were observed, were found in patients l, 2 and 7. Although previously reported [4] , the prevalence of this atypical form of VL was unclear. Most studies have shown that, among HIVinfected patients, the sensitivity of IFAT and ELISA is low [3, 4] . However, western blotting is more sensitive and may help discriminate asymptomatic carriage of Leishmania infection from acute VL [11] . For areas where Leishmania infection is endemic, we have recently proposed the use of systematic investigation consisting of western blotting and careful followup of patients with a serologic profile of latent infection [11] . This approach might allow for earlier systematic diagnosis of VL, rather than merely fortuitous diagnosis.
In conclusion, our data suggest that, in HIV-infected patients, clinical presentation of VL may be influenced by CD4 count. The clinical manifestations may be typical of VL or nonspecific (e.g., diarrhea), and the illness may become more atypical as the CD4 count decreases. Physicians in areas where Leishmania infection is endemic should be encouraged to test for such infection by use of western blotting and to consider a diagnosis of VL more routinely for HIV-infected patients.
Prolonged Suppression of Human Immunodeficiency Virus Type 1 RNA during Dual Nucleoside ReverseTranscriptase-Inhibitor Therapy in Clinical Practice
Because there is limited information about suppression of virus loads (determined by current "ultrasensitive" assays) in patients receiving nucleoside reverse-transcriptase inhibitors (NRTIs) alone, we reviewed our experience in clinical practice with patients who had virus loads of !25 copies/mL after 11 year of treatment with dual NRTIs. 
